跳到正文
OurGMP· 荀令君18·· 23 小时前精选AI 评分77

FDA 对 Genzyme 爱尔兰沃特福德厂签发 483,列 6 项观察

赛诺菲爱尔兰子公司Genzyme的FDA 483

AI 导读

FDA 于 2026 年 1 月 12 日至 20 日检查 Genzyme Ireland Limited 沃特福德厂,并于 1 月 20 日签发 483,列 6 项观察。

推荐理由

材料逐条译出6项观察及涉及的产品、批号和日期,便于核对实验室记录、厂房维护与偏差处理的具体缺陷。

正文
微信视频号封面
微信视频号 · OurGMP

赛诺菲爱尔兰子公司Genzyme的FDA 483
#FDA #483

在微信原文观看视频号

受检企业:Genzyme Ireland Limited,爱尔兰沃特福德郡 Unit 701, Ida Industrial Park,

Old Kilmeaden Road, Waterford, X91 TP27

检查日期:2026/1/12–1/20(共 7 个检查日)

签发日期:2026/1/20 正文共 9 页、6 项观察;

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

在对贵公司进行检查期间,我们观察到:

OBSERVATION 1 观察项 1(原文第 1–3 页)

Laboratory records are deficient in that they do not include a complete record of all data obtained during testing.

实验室记录存在缺陷,未包含检测过程中获得的全部数据的完整记录。

Specifically, deficiencies in documentation and data integrity were identified in environmental monitoring and (b)(4) testing records. The records and data for these quality control activities do not demonstrate adequate integrity controls and documentation practices.

具体而言,在环境监测与 (b)(4) 检测记录中发现文件记录与数据完整性方面的缺陷。这些质量控制活动的记录与数据未能体现充分的完整性控制及文件记录规范。

A) Failing non-viable particulate testing data present in the history of (b)(4) Particle Counters is not investigated for product impact, documented as a part of the testing record, or otherwise evaluated. Instances of such findings are summarized as follows:

A) (b)(4) 粒子计数器历史记录中出现的不合格非活性微粒检测数据,未就产品影响开展调查、未作为检测记录的一部分予以记录,也未作其他评估。此类发现汇总如下:

No. 1 (3-Jan-2025): Action level excursion not reported; No. 2 (3-Feb-2025): Action level excursion not reported; No. 3 (18-Aug-2025): Alert level excursion not reported; No. 4 (15-Jul-2025): Alert level excursion not reported; No. 5 (13-Sep-2025): Action level excursion (b)(4) not reported; No. 6 (27-Nov-2025): Alert level excursion not reported. [Table columns Controlled Form, Sampling Location, Official Documentation, Instrument Data, and Acceptance Criteria for ≥0.5 μm particles are redacted as (b)(4).] *Initial, unreported result from (b)(4) testing events.

第 1 项(2025 年 1 月 3 日):行动水平超标未报告;第 2 项(2025 年 2 月 3日):行动水平超标未报告;第 3 项(2025 年 8 月 18 日):警戒水平超标未报告;第 4 项(2025 年 7 月 15 日):警戒水平超标未报告;第 5 项(2025 年 9 月 13 日):行动水平超标 (b)(4) 未报告;第 6 项(2025 年 11 月 27 日):警戒水平超标未报告。〔表中“受控表单”“取样位置”“官方文件”“仪器数据”“≥0.5 μm 粒子可接受标准”各列均以 (b)(4) 遮盖。〕* 来自 (b)(4) 检测事件的初始未报告结果。

Note: All particle counts are reported as particles per cubic meter (particles/m3). Examples 3-6 involved (b)(4) testing events where only the (b)(4) result was reported on the controlled form, while the (b)(4) results showing excursions were not documented in official records.

注:所有粒子计数均以每立方米粒子数(particles/m³)表示。第 3 至 6 项涉及(b)(4) 检测事件:受控表单上仅报告了 (b)(4) 结果,而显示超标的 (b)(4) 结果未记入官方记录。

B) The data present on (b)(4) Air Samplers used in active air monitoring does not support the conduct of the respective environmental monitoring, showing inconsistencies between documented sampling activities and actual instrument usage records. Examples are listed below:

B) 用于主动空气监测的 (b)(4) 空气采样器所存数据,无法支持相应环境监测确已实施,反映出已记录的取样活动与仪器实际使用记录之间存在不一致。示例如下:

No. 1: Lack of accountability between active air monitor and environmental monitoring documentation; No. 2: Lack of accountability between active air monitor and environmental monitoring documentation; No. 3: Testing absent from instrument history; No. 4: Testing absent from instrument history; No. 5: Testing absent from instrument history. [Table columns Date, Controlled Form, Air Samplers Used, Documentation Claims, and Instrument Data Shows are redacted as (b)(4).]

第 1 项:主动空气监测仪与环境监测文件之间缺乏对应可追溯性;第 2 项:主动空气监测仪与环境监测文件之间缺乏对应可追溯性;第 3 项:仪器历史记录中无该次检测;第 4 项:仪器历史记录中无该次检测;第 5 项:仪器历史记录中无该次检测。〔表中“日期”“受控表单”“所用空气采样器”“文件声称内容”“仪器数据显示”各列均以 (b)(4) 遮盖。〕

C) Failing (b)(4) testing is not investigated. Specifically, procedure (b)(4)-SOP-0071168 titled "(b)(4) Testing" Section 5.15 reads "If the (b)(4) fails a (b)(4) refer to (b)(4) SOP-0070985 'Deviations and Investigations', Process Engineering will raise a customer complaint. The investigation and root cause analysis along with the conclusive testing result must be referenced in the EBR." Despite the procedure, the testing history of the (b)(4) instruments indicate testing events where more than one failure was encountered, but no accompanying deviation was raised. Further, the electronic batch records fail to document the (b)(4) failures, and Altuviiio batches (b)(4) and (b)(4) have been released. These findings are tabulated below:

C) 不合格的 (b)(4) 检测未开展调查。具体而言,规程 (b)(4)-SOP-0071168《“(b)(4) 检测”》第 5.15 节规定:“若 (b)(4) 未通过 (b)(4),参照 (b)(4) SOP-0070985《偏差与调查》,由工艺工程部门发起客户投诉。调查、根本原因分析以及最终检测结果必须在电子批记录(EBR)中引用。”尽管有此规定,(b)(4) 仪器的检测历史显示存在多次失败的检测事件,却未发起相应偏差。此外,电子批记录未记载上述 (b)(4)失败,且 Altuviiio 批次 (b)(4) 与 (b)(4) 已放行。这些发现列表如下:

Batch Number: (b)(4). Product (nine entries): Altuviiio; Altuviiio; (b)(4); Altuviiio; (b)(4) (merged across two rows); Altuviiio; Thymoglobulin; (b)(4). Number of Testing Failures: (b)(4). Deviation: No for all nine entries.

批号:(b)(4)。产品(9 条记录):Altuviiio;Altuviiio;(b)(4);Altuviiio;(b)(4) (跨两行合并);Altuviiio;Thymoglobulin;(b)(4)。检测失败次数:(b)(4)。偏差:9 条记录均为 No(未发起偏差)。

D) Official records are inconsistent with Good Documentation Practices:

D) 官方记录不符合良好文件规范(Good Documentation Practices):

1) Your firm utilizes "Review Checklist" to unofficially document findings of Quality Control document reviews. The "Review Checklist" is subsequently (b)(4). Moreover, a review of the "Review Checklist" identified entries that were made non-contemporaneously that were not attributed as such. The "Review Checklist" pertaining to December 16, 2025 reads "'yes' not circled for Acceptance criteria" and "Sample results not entered." However, the corresponding record ((b)(4)-0115397) contains a circled 'yes' and incorporates the sample results without documentation that these entries are retrospective.

1) 贵公司使用“审核检查表”(Review Checklist)以非正式方式记录质量控制文件审核的发现,该检查表随后被 (b)(4)。此外,对该检查表的审查发现存在非同步填写、且未标注为事后补记的条目。2025 年 12 月 16 日的“审核检查表”记载“'yes' 未圈选(可接受标准)”及“未录入样品结果”,但对应记录 ((b)(4)-0115397) 中却已圈选 'yes'并录入了样品结果,且未说明这些条目属于事后追溯补录。

2) The logbooks documenting the entrance and exit times from the cleanrooms are inconsistent with the sampling times for environmental monitoring. Specifically, personnel conducting environmental monitoring are not documented as being present in the cleanroom at the times the sampling was conducted. For example, on October 13, 2025, environmental monitoring personnel are documented as being present in the cleanroom between (b)(4) however, environmental monitoring is documented as being conducted from (b)(4).

2) 记录洁净室进出时间的台账与环境监测取样时间不一致。具体而言,实施环境监测的人员在取样进行时段并未被记录为在洁净室内。例如,2025 年 10 月 13 日,环境监测人员被记录为在 (b)(4) 期间位于洁净室内,但环境监测却记录为自 (b)(4) 起实施。

3) Your firm uses (b)(4) to instruct personnel to review/revise records. On January 19, 2026, (b)(4) encompassing review comments were observed in on official documentation in the Quality Control area. Your procedure (b)(4).0034155 entitled "Data Integrity" states "The use of (b)(4) is not permitted in GMP areas."

3) 贵公司使用 (b)(4) 指示人员审核/修订记录。2026 年 1 月 19 日,在质量控制区域的官方文件上观察到 (b)(4) 所涵盖的审核意见。贵公司规程 (b)(4).0034155《数据完整性》规定:“GMP 区域内不得使用 (b)(4)。”

OBSERVATION 2 观察项 2(原文第 4–6 页)

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

适用于质量控制部门的职责与规程未形成书面文件并得到完全执行。

Specifically, your procedure requires a change control to be issued for implementing changes. This requirement is delineated in SOP (b)(4)-0000514 titled "Change Control Management". However, several examples were found where a Work Order was used for conducting investigations instead of following the established change control procedure. Examples include but are not limited to:

具体而言,贵公司规程要求实施变更须签发变更控制,该要求载于 SOP (b)(4)-0000514《变更控制管理》。然而发现多起以工单(Work Order)开展调查、而未遵循既定变更控制程序的情形。示例包括但不限于:

A) There is no procedure to differentiate when events should be documented as a deviation or a work order. Thus, leakage events throughout your facility have been documented as work orders, without a corresponding deviation. Additionally, the work orders have not been the subject of quality oversight and the impact of the event on the facility and associated products have not been performed. Additionally, these work orders have not been trended. For example, the following leaks have been documented as work orders without a corresponding deviation:

A) 没有规程区分何类事件应记为偏差、何类应记为工单。因此,全厂区的泄漏事件均记为工单,未伴随相应偏差。此外,这些工单未纳入质量监管,未评估事件对设施及相关产品的影响,也未进行趋势分析。例如,以下泄漏事件仅记为工单而未发起相应偏差:

Work Order 3296872 (Opened January 09, 2025): "Investigation/Actions - A water leak was identified on the (b)(4) (b)(4). On investigation it was found that the (b)(4) was found to not be (b)(4) and was leaking."

工单 3296872(开立日期 2025 年 1 月 9 日):“调查/措施——在 (b)(4) (b)(4)发现一处漏水。经调查发现,该 (b)(4) 未处于 (b)(4) 状态并正在漏水。”

Work Order 3296870 (Opened January 09, 2025): "Investigation/Actions - Water was visible on the ground at the (b)(4) (b)(4). On investigation it was found that there were intermittent drops from the (b)(4) (b)(4) and the leak stopped." "Closing Comments - There was no impact on the operation of the system due to this leak and no impact on the operation of the system while repairing leak."

工单3296870(开立日期 2025 年 1 月 9 日):“调查/措施——(b)(4) (b)(4) 地面可见积水。经调查发现 (b)(4) (b)(4) 有间歇性滴水,随后泄漏停止。”“关闭意见——该泄漏未影响系统运行,修复泄漏期间亦未影响系统运行。”

Work Order 3382891 (Opened August 16, 2025): "Water leaking from (b)(4) with no issues noted, (b)(4) closed and inspected from opposite side and no gaps appeared to be present. (b)(4) water leaked from under (b)(4) immediately. (b)(4) stopped to ensure no further water leaked out."

工单 3382891(开立日期 2025 年 8 月 16 日):“(b)(4) 处漏水,未发现异常,(b)(4) 已关闭并从另一侧检查,未见缝隙。(b)(4) 立即从 (b)(4) 下方漏出。(b)(4) 已停机以确保不再漏水。”

Work Order 3384466 (Opened August 20, 2025): "This work order is associated with work order 3382891 and states (b)(4) 'leaking' with the investigation identifying (b)(4) liquid was seen coming from (b)(4) (b)(4) leak stopped."

工单 3384466(开立日期 2025 年 8 月 20 日):“本工单与工单 3382891 关联,记载 (b)(4)‘泄漏’,调查确认 (b)(4) 液体自 (b)(4) (b)(4) 流出,泄漏已停止。”

Work Order 3301730 (Opened January 22, 2025): "Action/Investigation - leak coming for (b)(4) leak stopped."

工单 3301730(开立日期 2025 年 1 月 22 日):“措施/调查——(b)(4) 处来水泄漏,泄漏已停止。”

Work Order 3324758 (Opened March 21, 2025): "Investigation/Actions - Water leak on floor underneath (b)(4) identified during (b)(4) on 20 Mar 25. There was initially no sign of the source of the leak in the area at the time. Water was cleaned up and area monitored. On 21 Mar 25 water was again evident in the area. On this occasion water was seen dripping from the (b)(4) (b)(4) and the leak stopped. Residual water was cleaned up and area was monitored with no further issues."

工单 3324758(开立日期 2025 年 3 月 21 日):“调查/措施——3 月 20 日于(b)(4) 期间发现 (b)(4) 下方地面漏水。当时该区域未见泄漏源迹象,已清理积水并对区域进行监控。3 月 21 日该区域再次出现积水,此次可见水自 (b)(4) (b)(4) 滴落,随后泄漏停止。残留积水已清理,区域持续监控,未再出现问题。”

B) Your firm failed to adequately review production records to ensure that no errors have occurred or, if errors have occurred, that they have been fully investigated. There have been failed (b)(4) for (b)(4) (b)(4) since January 2025, attributed by your Area Engineering & Maintenance Manager to improperly (b)(4). No retrospective batch impact assessment has been conducted for these failures, and these recurring events have not been subject to deviation reporting or quality oversight review. Filling Line (b)(4) accounts for approximately 34% of these work orders. Your firm has not conducted retrospective batch impact assessments for these failures, has not subjected these recurring events to deviation reporting or quality oversight review, and has not evaluated whether (b)(4) was compromised during previous batches manufactured using the Grade (b)(4). Line (b)(4) is utilized routinely for filling of U.S. marketed products, including Thymoglobulin and Altuviiio.

B) 贵公司未充分审核生产记录,以确保未发生差错,或一旦发生差错已得到全面调查。自 2025 年 1 月以来,(b)(4) (b)(4) 多次出现 (b)(4) 失败,贵公司区域工程与维护经理将其归因于 (b)(4) 不当。针对这些失败未开展回顾性批次影响评估,此类反复发生的事件也未纳入偏差报告或质量监管审核。灌装线 (b)(4) 约占这些工单的 34%。贵公司未就这些失败开展回顾性批次影响评估,未将反复事件纳入偏差报告或质量监管审核,也未评估在 Grade (b)(4) 既往生产批次中 (b)(4) 是否受到损害。灌装线 (b)(4)常规用于美国上市产品的灌装,包括 Thymoglobulin 与 Altuviiio。

C) GMP Permit 240002415 was initiated for Fill Line (b)(4) under Work Order 3350858 to investigate (b)(4) functionality. The investigation was prompted by (b)(4) issues observed during the filling of a previous batch (b)(4) on Fill Line (b)(4). The investigation was conducted under the GMP permit on June 6, 2025. No deviation was initiated for batch (b)(4) in connection with the observed (b)(4) issues.

C) 依据工单 3350858,就灌装线 (b)(4) 启动了 GMP 许可证 240002415,以调查(b)(4) 功能。该调查缘于此前在灌装线 (b)(4) 灌装批次 (b)(4) 期间观察到的 (b)(4) 问题。调查于 2025 年 6 月 6 日在该 GMP 许可证下实施,但未就所观察到的 (b)(4) 问题对批次 (b)(4) 发起偏差。

D) In May 2025, a portion of the (b)(4) in the Grade (b)(4) filling line (b)(4) was identified as a trip hazard. The work order was initiated on January 15, 2026. The GMP permit 260002854 was initiated on January 9, 2026, and approved (by QA) as complete on January 15, 2026. During the inspectional walkthrough on January 13, 2026, we observed that Fill Line (b)(4) was actively being used to fill batch # (b)(4) Thymoglobulin, while this GMP Permit remained open and incomplete. Furthermore, the work order (3447495) was initiated after the FDA made this observation during the inspectional walkthrough.

D) 2025 年 5 月,Grade (b)(4) 灌装线 (b)(4) 的 (b)(4) 局部被确认为绊倒隐患。工单于 2026 年 1 月 15 日才发起;GMP 许可证 260002854 于 2026 年 1 月 9 日发起,并于 2026 年 1 月 15 日经 QA 批准为完成。在 2026 年 1 月 13 日的检查巡视中,我们观察到灌装线 (b)(4) 正用于灌装 Thymoglobulin 批次 # (b)(4),而该 GMP 许可证仍处于开放未完成状态。此外,工单 (3447495) 是在 FDA 于检查巡视中提出该观察之后才发起的。

E) Your (b)(4) electronic quality management system revealed that you cancelled 74 deviations between February 6, 2024, and January 12, 2026. Your cancelled deviations demonstrate a pattern of data entry errors and procedural failures that were not investigated for root cause or addressed through your quality management system. Examples of cancelled deviations include:

E) 贵公司 (b)(4) 电子质量管理系统显示,2024 年 2 月 6 日至 2026 年 1 月 12 日期间共取消 74 项偏差。被取消的偏差呈现出数据录入错误与程序执行失效的模式,既未调查根本原因,也未通过质量管理系统加以处置。被取消偏差的示例包括:

QE-025817 was initiated on April 11, 2025, for Thymoglobulin batch (b)(4) after a team member observed a broken vial on the (b)(4) (b)(4). The deviation was subsequently cancelled based on a QA Expert Comment stating that "(b)(4) Fill (b)(4) does not give instruction or advisory for a deviation to be raised in relation to the discovery of a broken vial in the (b)(4), therefore, QE-025817 will be cancelled." The cancellation of this deviation resulted in no evaluation of the potential implications of the broken vial incident. The firm did not assess potential contamination risks to the batch, evaluate the integrity of the sterile environment, determine if other vials in the batch were compromised, implement corrective and preventive actions, or document the incident for future reference. The deviation was closed without investigation of the quality event.

QE-025817 于 2025 年 4 月 11 日针对 Thymoglobulin 批次 (b)(4) 发起,起因是团队成员在 (b)(4) (b)(4) 发现一只破损西林瓶。该偏差随后依据一条 QA 专家意见被取消,意见称:“(b)(4) 灌装 (b)(4) 未就 (b)(4) 内发现破损西林瓶须发起偏差给出指令或建议,故取消 QE-025817。”取消该偏差导致破损瓶事件的潜在影响完全未获评估:企业未评估批次潜在污染风险、未评价无菌环境完整性、未判定同批其他西林瓶是否受影响、未实施纠正与预防措施,也未将该事件留档备查。该质量事件未经调查即关闭偏差。

QE-137282 (initiated April 7, 2025): Cancelled after (b)(4) reclassified 13 defects from (b)(4) (b)(4) to "Incorrect Fill Level (b)(4)", reducing percentage from (b)(4) to (b)(4) below reject limit.

QE-137282(2025 年 4 月 7 日发起):在 (b)(4) 将 13 项缺陷由 (b)(4) (b)(4) 重新归类为“灌装量不正确 (b)(4)”后被取消,占比由 (b)(4) 降至低于拒收限的 (b)(4)。

QE-163002 (initiated May 9, 2025): Cancelled as "raised in error" for incorrect defect type entry "foreign matter on body" in EBR defect log.

QE-163002(2025 年 5 月 9 日发起):因电子批记录缺陷日志中缺陷类型误录为“瓶身异物”,以“误发起”为由取消。

QE-152679 (initiated July 1, 2025): Cancelled for missing logbook entries based on "presence of a second GMP source".

QE-152679(2025 年 7 月 1 日发起):因台账条目缺失,以“存在第二份 GMP原始记录”为由取消。

QE-134066 (initiated March 27, 2025): Cancelled for incorrect (b)(4) confirmed from original GMP source with manufacturing and QA agreement.

QE-134066(2025 年 3 月 27 日发起):经生产部门与 QA 确认原始 GMP 记录后,因 (b)(4) 有误而取消。

QE-094631 (initiated November 17, 2024): Cancelled as "raised in error, no longer required and can be voided" with original deviation description overwritten.

QE-094631(2024 年 11 月 17 日发起):以“误发起、不再需要、可作废”为由取消,且原始偏差描述被覆盖。

QE-090910 (initiated November 5, 2024): Cancelled as "raised in error and no longer required" for incorrect (b)(4) number logging ((b)(4) vs (b)(4)) with original fields overwritten.

QE-090910(2024 年 11 月 5 日发起):因 (b)(4) 编号记录有误((b)(4) 与(b)(4)),以“误发起且不再需要”为由取消,原始字段被覆盖。

You confirmed that no retrospective impact assessment was conducted for these cancelled deviations. All deviations pertain to U.S. marketed products.

贵公司确认,未就这些被取消的偏差开展回顾性影响评估。所有偏差均涉及美国上市产品。

OBSERVATION 3 观察项 3(原文第 6–7 页)

Buildings used in the manufacturing, processing and holding of a drug product are not maintained in a good state of repair.

用于药品生产、加工与存放的厂房未保持良好维修状态。

Specifically, the following conditions were observed in your fill/finish manufacturing areas during the current inspection:

具体而言,本次检查期间在贵公司灌装/分装生产区域观察到以下状况:

A) On January 13, 2026, in Room (b)(4) (Fill Line (b)(4)), the (b)(4) exhibited two "X" shaped cracks that were actively extruding water during the (b)(4) operations utilizing (b)(4). The intersecting cracks created four distinct arms, each measuring approximately 4 to 5 inches in length. Your firm's personnel stated they had been aware of these cracks since October 2025, yet continued manufacturing operations without adequate documentation or quality assessment of the water leak's impact on product quality. Despite awareness of (b)(4) cracks since October 2025 and ordering replacement parts in October 2025, there was an absence of GMP documentation regarding the (b)(4) condition until January 12, 2026. No quality documentation addressed the impact of active water leakage from the equipment cracks. Batch (b)(4) Thymoglobulin, was being filled on January 13, 2026, when this observation was made.

A) 2026 年 1 月 13 日,在 (b)(4) 房间(灌装线 (b)(4)),(b)(4) 出现两处 “X” 形裂纹,在使用 (b)(4) 实施 (b)(4) 操作期间正持续向外渗水。交叉裂纹形成四条明显分支,每条长约 4 至 5 英寸。贵公司人员称自 2025 年 10 月起即已知悉这些裂纹,却仍继续生产,未就漏水对产品质量的影响作出充分记录或质量评估。尽管自 2025 年 10月即知悉 (b)(4) 裂纹并于当月订购备件,直至 2026 年 1 月 12 日仍无关于该 (b)(4) 状况的 GMP 文件记录,也无任何质量文件论及设备裂纹持续渗水的影响。作出该观察时(2026 年 1 月 13 日),正在灌装 Thymoglobulin 批次 (b)(4)。

B) On January 12-13, 2026, in the Grade (b)(4) area (Room (b)(4)) of Fill Line (b)(4), HEPA filters supplying clean air exhibited reddish brown discoloration consistent with rust. (b)(4) particulate matter consistent with (b)(4) was observed on the Grade (b)(4) floor, and localized areas accumulated significant (b)(4) residue. Batch (b)(4) of Myozyme was being filled when this observation was made.

B) 2026 年 1 月 12 至 13 日,在灌装线 (b)(4) 的 Grade (b)(4) 区域((b)(4) 房间),供应洁净空气的 HEPA 高效过滤器呈现与锈蚀一致的红褐色变色;Grade (b)(4)地面观察到与 (b)(4) 一致的 (b)(4) 微粒物质,局部区域积聚大量 (b)(4) 残留物。作出该观察时,正在灌装 Myozyme 批次 (b)(4)。

C) During the inspectional walkthrough on January 13, 2026, we observed a section in the Grade (b)(4) Filling Line (b)(4) (Room (b)(4)) where a portion of the (b)(4) had been removed. The floor in this area exhibited visible discoloration and stains. Multiple holes remained in the floor from the removal of (b)(4) (b)(4). At least one of the holes contained visible blackish-brown liquid of unknown origin. Thymoglobulin batch (b)(4) was being filled in the room while this observation was made.

C) 在 2026 年 1 月 13 日的检查巡视中,我们在 Grade (b)(4) 灌装线 (b)(4)((b)(4)房间)观察到一段区域的 (b)(4) 已被拆除。该区域地面可见变色与污渍,拆除 (b)(4)(b)(4) 后地面留下多个孔洞,至少一个孔洞内可见来源不明的黑褐色液体。作出该观察时,该房间正在灌装 Thymoglobulin 批次 (b)(4)。

Note: Fill lines (b)(4) and (b)(4) are routinely used for U.S. marketed drug products,including Thymoglobulin and Altuviiio.

注:灌装线 (b)(4) 与 (b)(4) 常规用于美国上市药品的生产,包括 Thymoglobulin与 Altuviiio。

OBSERVATION 4 观察项 4(原文第 7–8 页)

Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

设备与器具未按适当间隔进行清洁和维护,以防止足以改变药品安全性、鉴别、含量、质量或纯度的污染。

Specifically,

具体如下:

A) On January 12, 2026, filling (b)(4) used for (b)(4) contained unknown brownish white residue around the (b)(4). Internal inspection revealed brownish red discoloration consistent with rust on product contact surfaces, which your firm confirmed as "active corrosion." This (b)(4) was recently used to manufacture Myozyme batch (b)(4). This (b)(4) is used for routine manufacturing of U.S. marketed products.

A) 2026 年 1 月 12 日,用于 (b)(4) 的灌装 (b)(4) 在 (b)(4) 周围存在来源不明的棕白色残留物。内部检查发现产品接触表面有与锈蚀一致的棕红色变色,贵公司确认为“活性腐蚀”(active corrosion)。该 (b)(4) 近期用于生产 Myozyme 批次 (b)(4),并常规用于美国上市产品的生产。

B) On January 12, 2026, filling (b)(4) exhibited similar internal product contact surface deterioration with brownish red discoloration and scratches/abrasions to the (b)(4) interior, confirmed by your firm as "scratches and gouges" and "active corrosion." This (b)(4) was recently used to manufacture Thymoglobulin batches (b)(4) and (b)(4). This is used for routine manufacturing of U.S. marketed products.

B) 2026 年 1 月 12 日,灌装 (b)(4) 出现类似的产品接触表面内部劣化,(b)(4) 内壁有棕红色变色及划痕/磨损,贵公司确认为“划痕与沟槽”(scratches and gouges)及“活性腐蚀”。该 (b)(4) 近期用于生产 Thymoglobulin 批次 (b)(4) 与 (b)(4),并常规用于美国上市产品的生产。

C) During the filling of Thymoglobulin batch (b)(4) on January 13, 2026, a stopper was discovered on the floor beneath the (b)(4) in Room (b)(4). The stopper was located upstream from (b)(4) filling line. Manufacturing personnel indicated that the stopper could have fallen during (b)(4) operations when the (b)(4) are challenged.

C) 2026 年 1 月 13 日灌装 Thymoglobulin 批次 (b)(4) 期间,在 (b)(4) 房间 (b)(4)下方地面发现一枚胶塞,其位置处于 (b)(4) 灌装线的上游。生产人员表示,该胶塞可能是在 (b)(4) 操作、(b)(4) 接受挑战测试时掉落。

OBSERVATION 5 观察项 5(原文第 8–9 页)

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

未能对任何无法解释的差异,以及批次或其任何组分不符合任何质量标准的情况进行彻底审核,无论该批次是否已销售流通。

Specifically,

具体如下:

A) Complaint 493112 pertaining to "Foreign Matter After Reconstitution" found in Thymoglobulin lot (b)(4) described brown particulate or blemish on the inside of the vial that was removable when wiped with a cloth. The associated Deviation WATD23E0198 documented that during inspection of Thymoglobulin batch (b)(4) vials were rejected for the (b)(4) defect of foreign matter on stopper, with (b)(4) vials classified as (b)(4) foreign matter. Your firm's engineering investigation concluded that "the most probable root cause of the Foreign Matter observed in PE 100378833 is (b)(4) as a consequence of the (b)(4) manufacturing process." Despite identifying the manufacturing process as the most probable root cause of this critical defect, your firm classified the deviation as (b)(4) and deemed the finding non-reportable. Your firm's justification that removing defective vials negated the impact of the deviation, fails to address the underlying manufacturing process deficiency that generated the foreign matter contamination. Batch (b)(4) was released to the U.S. market (Expired (b)(4)).

A) 投诉 493112 涉及 Thymoglobulin 批号 (b)(4) 中发现的“复溶后异物”,描述为西林瓶内壁的棕色微粒或瑕疵,用布擦拭即可去除。关联偏差 WATD23E0198 记载:

在检查 Thymoglobulin 批次 (b)(4) 时,有西林瓶因 (b)(4) 类“胶塞异物”缺陷被剔除,其中 (b)(4) 瓶被归为 (b)(4) 异物。贵公司工程调查结论为:“PE 100378833 中观察到的异物,最可能的根本原因是 (b)(4),系 (b)(4) 生产工艺所致。”尽管已将生产工艺认定为该关键缺陷的最可能根本原因,贵公司仍把该偏差归类为 (b)(4),并判定该发现无需报告。贵公司以“剔除缺陷瓶即消除偏差影响”作为理由,未能解决产生异物污染的根本工艺缺陷。批次 (b)(4) 已放行至美国市场(已过期 (b)(4))。

B) Deviation WATD23E0838 documented OOS activity results of (b)(4) for batch (b)(4) at the (b)(4) Bioburden (b)(4) stage and an OOS result for PPQ batch (b)(4) at the (b)(4) stage. The firm's investigation concluded that sample contamination with (b)(4) during (b)(4) was the probable root cause and determined "no impact to the PPQ program." However, this conclusion was based on a hypothesis of sample contamination with (b)(4) that lacked sufficient evidence.

B) 偏差 WATD23E0838 记载:批次 (b)(4) 在 (b)(4) 生物负载 (b)(4) 阶段出现(b)(4) 的 OOS(超标)活性结果,PPQ 批次 (b)(4) 在 (b)(4) 阶段亦出现 OOS 结果。企业调查结论认为,(b)(4) 期间样品被 (b)(4) 污染是最可能的根本原因,并判定“对 PPQ项目无影响”。然而,该结论所依据的“样品被 (b)(4) 污染”假设缺乏充分证据。

OBSERVATION 6 观察项 6(原文第 9 页)

Deviations from written production and process control procedures are not justified.

偏离书面生产与过程控制规程的情形未得到论证说明。

Specifically, Batch (b)(4) of Thymoglobulin was filled under conditions that significantly deviated from qualified operating conditions within the Grade (b)(4). During inspectional walkthrough on January 13, 2026, we observed the (b)(4) and (b)(4) overflowed due to a malfunctioning (b)(4) causing (b)(4) to (b)(4) on the fill line and (b)(4) necessary for maintaining (b)(4). The blocked (b)(4) compromised the (b)(4) ability to maintain the required (b)(4) for Grade (b)(4) environmental classification. No deviation was raised for these non-conforming conditions, and the decision to proceed with batch filling was made under a work order without proper risk assessment of the altered environmental conditions. (b)(4) studies conducted under dynamic conditions demonstrate that these (b)(4) must remain clear of obstructions to maintain (b)(4) (b)(4) during the (b)(4) operation.

具体而言,Thymoglobulin 批次 (b)(4) 是在显著偏离 Grade (b)(4) 已确认运行条件的状况下灌装的。在 2026 年 1 月 13 日的检查巡视中,我们观察到 (b)(4) 与 (b)(4)因 (b)(4) 故障而溢出,导致 (b)(4) 在灌装线上 (b)(4),并影响维持 (b)(4) 所必需的(b)(4)。被堵塞的 (b)(4) 削弱了 (b)(4) 维持 Grade (b)(4) 环境分级所需 (b)(4) 的能力。针对这些不符合状况未发起任何偏差,且继续灌装该批次的决定是在工单下作出的,未对改变后的环境条件进行适当风险评估。在动态条件下开展的 (b)(4) 研究表明,这些(b)(4) 必须保持无遮挡,才能在 (b)(4) 操作期间维持 (b)(4) (b)(4)。

微信视频号封面
微信视频号 · OurGMP

吉林某制药公司FDA 483解析,涉及2条观察项,分别涵盖清洁验证和工艺验证。

在微信原文观看视频号

来源:OurGMP · mp.weixin.qq.com